astellas pharma inc-unsp adr
(ALPMY:OTC Markets Group Inc - Current Information)
Transactions by ASTELLAS PHARMA INC-UNSP ADR (ALPMY) in the last 6 months
Kanyos Bio, Inc. announced that it will receive $16,409,144 in funding on May 29, 2015. The company will issue common stock in the transaction. The company will issue securities pursuant to exemption provided under Regulation D. On June 2, 2015, the company announced that the transaction includes participation from new investor Astellas Pharma, Inc. along with Anokion SA’s existing investors.
Astellas Pharma Inc. (TSE:4503) announces a share repurchase program. Under the program, the company will repurchase up to 20,000,000 shares, representing 0.91% of its outstanding share capital, for a total cost of ¥40,000 million. The purpose of the plan is to improve capital efficiency and shareholder return. The repurchases will be made until July 24, 2015. As of March 31, 2015, the company had 2,193,141,515 shares outstanding and 66,681,660 shares in treasury.
|Becton Dickinson and Co||$152.35 USD||-0.08|
|Boston Scientific Corp||$17.09 USD||-0.02|
|CSL Ltd||A$100.77 AUD||+1.94|
|Mylan NV||$54.67 USD||-0.53|
|Solvay SA||€120.35 EUR||+0.15|
|View Industry Companies|